Monoclonal Antibody

Daratumumab

Daratumumab is a monoclonal antibody that targets CD38.

Research Overview

CD38 is a target of interest in hematological oncology. Daratumumab is included in CHENGENE's monoclonal antibody research portfolio.

Research Enquiry ↗

CHENGENE PRIVATE LIMITED

Advancing biotechnology through research.

Contact our team for further information about CHENGENE's research and development portfolio. Product availability, development status and regulatory details should be confirmed directly with the company.